Novartis (VTX:NOVN) received a CHF 84 price objective from analysts at Credit Suisse Group in a research note issued on Friday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock.
Several other research firms have also issued reports on NOVN. Kepler Capital Markets set a CHF 86 price target on Novartis and gave the company a “buy” rating in a report on Tuesday, April 16th. JPMorgan Chase & Co. set a CHF 85 price target on Novartis and gave the company a “sell” rating in a report on Tuesday, April 9th. Jefferies Financial Group set a CHF 95 price target on Novartis and gave the company a “buy” rating in a report on Thursday, April 25th. Goldman Sachs Group set a CHF 110 price target on Novartis and gave the company a “buy” rating in a report on Monday, March 25th. Finally, HSBC set a CHF 86 price target on Novartis and gave the company a “neutral” rating in a report on Wednesday, February 6th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of CHF 88.35.
Novartis has a fifty-two week low of CHF 72.45 and a fifty-two week high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Featured Story: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.